Articles by Patrick Daly
Monotherapy with tagraxofusp induced complete remissions in patients with blastic plasmacytoid dendritic cell neoplasm.
The ELM-2 trial studied odronextamab in patients with relapsed or refractory follicular lymphoma.
FLAG-IDA or DA plus gemtuzumab ozogamicin had differing performance in younger patients with newly diagnosed AML.
MRD status after induction chemotherapy predicted benefit from allogeneic transplant in patients with NPM1-mutated AML.
Low-dose azacitidine plus venetoclax was a feasible maintenance regimen in AML after intensive or low-intensity induction.
Loss of inhibitor of kappa B epsilon was found to drive NF-κB pathway activity and migration and proliferation of CLL cells.
CAR T-cell therapies effectively treated patients with Richter transformation, an aggressive subtype of CLL.
Patients with Richter transformation had improved outcomes when treated with venetoclax-based treatment regimens.
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
Catherine Coombs, MD, outlined some of her research into the solid tumor microenvironment, particularly in prostate cancer.
Dr Cliff describes an analysis of oncology drugs that were approved via the FDA Accelerated Approval Program over 10 years.
Paolo Ghia, MD, PhD talks about his session on monoclonal B-cell lymphocytosis presented at the AACR Annual Meeting 2024.
Tumor cells in high-risk follicular lymphoma had enhanced B-cell receptor signaling and distinct follicular growth patterns.
Claudio Cerchione, MD, PhD, describes his presentation from AACR 2024 on a emavusertib triplet in patients with AML.
The expansion of the indication was supported by positive data from the KarMMa-3 study.
The conference has a lot of great sessions, including an untraditional keynote speaker, Dr. Hastings said.
Monotherapy with pivekimab sunirine demonstrated activity in patients with relapsed or refractory CD123-positive AML.
Dr. Siddiqi shares data from the phase I/II TRANSCEND CLL 004 trial on liso-cel in patients with relapsed or refractory CLL.
The novel DuplexSeq AML-XP next-generation sequencing assay was highly accurate for detecting MRD in AML.
Treatment with ibrutinib plus FCR followed by ibrutinib maintenance induced durable and deep responses in patients with CLL.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.